Innovative therapeutics


Press Releases

Advanced Search
  • Nov 12, 2018
    First-of-its-Kind Musical Featuring 25 High-School Students Affected by Bleeding Disorders Premieres in Broadway Theater

    BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical production featuring 25 students affected by a...

  • Nov 8, 2018
    - Credit Suisse 27th Annual Credit Suisse Healthcare Conference on November 13 in Scottsdale, AZ

    BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in two investor conferences this November. To access the events that are accessible by live webcasts,...

  • Nov 7, 2018
    Vosoritide for Achondroplasia: Demonstrates Continued Increased Growth through 42 months in Phase 2; Global Phase 3 Fully Enrolled

    BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare and...

  • Nov 1, 2018
    Key Research & Development Pipeline Products and Data to be Presented, Including:

    BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day from 8:30am (ET) to 11:30am (ET) on Wednesday, November 7, 2018 in New York City. BioMarin management and external experts will...

  • Oct 25, 2018
    - First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion

    Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 % Change 2018 2017 % Change Total...

Show 5102550100 per page



Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS



Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361

Global Medical Information

Contact Global Medical Information